The PennZone

  • Home
  • Non-profit
  • Music
  • Marketing
  • Books
  • Entertainment
  • Health
  • Automotive
  • Business

SafER has announced a Stage 3 clinical trial evaluating the SafER Negative Pressure System reducing aerosol emissions during bronchoscopic procedures
The PennZone/10271927

Trending...
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
  • Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
Vacuum And Mask Respiratory Shield Endo Shield Hospital Nosuction 1 Hospital Suction 1c SafER Medical Products LLC
BRANSON, Mo. - PennZone -- Bronchoscopy is known to be an aerosol generating procedure and produce plumes of microscopic particles, some of which may carry infectious airborne organisms, that can then be inhaled by medical personnel in attendance and subsequently pose a high-risk of those medical staff contracting the disease.  "Our goal since the beginning of the pandemic has been to create a safer work environment for our friends and colleagues who are exposed to dangerous pathogens when performing aerosol generating procedures, while expanding access to those life-saving procedures for our patients", said SafER Chief Medical Officer, Dr. Rick Blubaugh.

The SafER system is the world's first portable negative pressure system that utilizes HEPA filtration to capture dangerous fugitive emissions at the source – the patient.  The system has been in use since the pandemic in hospitals, ambulances, and long-term facilities around the country and can be utilized during a variety of procedures including intubation, nebulizer, CPAP or Bi-Level PAP, endoscopy, and sputum or swab collection.

More on The PennZone
  • Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
  • "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026
  • Detroit Lawyer Steals $600,000 Settlement Meant to Protect Child
  • The Great Junk Hunt Makes Its Highly Anticipated Stop in Philadelphia (Oaks)!
  • Heritage at South Brunswick Announces Special Townhome Mortgage Rate Buydown

The study is randomized controlled and will take place in a 1,000-bed tertiary facility and is expected to enroll 80 patients over a 3-month period.  The goals of the study are to assess the system and the reduction of aerosol emissions produced during bronchoscopic procedures.  Results of the study are expected to be announced late this summer.

http://www.safermedicalproducts.com

Contact
Carl Baker
cbaker@safermedicalproducts.com


Source: SafER Medical Products LLC

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Lehigh County Drug and Alcohol Celebrates Grand Opening of Journeys
  • Timbrana Addresses the Missing Follow-Through in Commercial Construction Projects
  • AI Agents Are Getting Their Own Computers. HRTech Leading in Vertical Harness Development
  • UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
  • JKS Financial Gives Back Through Light of Life Rescue Mission Food Pantry
  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Corner Property Management AAMC Expands Presence with Clover Mill Management Agreement
  • Michael Fischer Launches 'Legacy League' Podcast
  • Keystone Consulting Engineers Marks Next Chapter of Growth with Refreshed Brand
  • AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
  • DayPass llega a ChatGPT y Claude
  • DayPass launches in ChatGPT and Claude
  • Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
  • Victor Archibong Expands ItsArchiDuh Creator Brand
  • Talented Learning Unveils 2026 LMS Award Winners
  • Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • Revinate launches hospitality's first data activation platform
  • HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
  • BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers - 139
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh - 104
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia
  • Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026

Similar on PennZone

  • Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event
  • Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
  • Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
  • Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton
  • Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
  • Lehigh County Drug and Alcohol Celebrates Grand Opening of Journeys
  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
  • Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us